Citadel Advisors’s Applied Genetic Technologies Corporation AGTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-423,709
| Closed | -$115K | – | 15926 |
|
|
2022
Q3 | $115K | Buy |
+423,709
| New | +$185K | ﹤0.01% | 10972 |
|
|
2022
Q2 | – | Sell |
-50,041
| Closed | -$44.6K | – | 14702 |
|
|
2022
Q1 | $53K | Sell |
50,041
-3,575
| -7% | -$6.5K | ﹤0.01% | 12759 |
|
|
2021
Q4 | $102K | Sell |
53,616
-50,554
| -49% | -$121K | ﹤0.01% | 12709 |
|
|
2021
Q3 | $313K | Sell |
104,170
-19,491
| -16% | -$69.4K | ﹤0.01% | 10987 |
|
|
2021
Q2 | $484K | Buy |
123,661
+34,538
| +39% | +$143K | ﹤0.01% | 10131 |
|
|
2021
Q1 | $452K | Buy |
+89,123
| New | +$462K | ﹤0.01% | 9898 |
|
|
2018
Q1 | – | Sell |
-16,533
| Closed | -$60K | – | 8968 |
|
|
2017
Q4 | $60K | Sell |
16,533
-24,737
| -60% | -$93.4K | ﹤0.01% | 7579 |
|
|
2017
Q3 | $163K | Buy |
+41,270
| New | +$190K | ﹤0.01% | 6818 |
|
|
2017
Q2 | – | Sell |
-21,426
| Closed | -$120K | – | 8262 |
|
|
2017
Q1 | $148K | Sell |
21,426
-22,590
| -51% | -$176K | ﹤0.01% | 6695 |
|
|
2016
Q4 | $412K | Buy |
44,016
+12,548
| +40% | +$113K | ﹤0.01% | 5213 |
|
|
2016
Q3 | $308K | Sell |
31,468
-35,983
| -53% | -$485K | ﹤0.01% | 5637 |
|
|
2016
Q2 | $953K | Sell |
67,451
-14,206
| -17% | -$222K | ﹤0.01% | 3612 |
|
|
2016
Q1 | $1.14M | Buy |
81,657
+38,554
| +89% | +$566K | ﹤0.01% | 3327 |
|
|
2015
Q4 | $879K | Buy |
+43,103
| New | +$665K | ﹤0.01% | 3740 |
|
|
2015
Q2 | – | Sell |
-17,762
| Closed | -$354K | – | 9203 |
|
|
2015
Q1 | $354K | Buy |
+17,762
| New | +$397K | ﹤0.01% | 5422 |
|
Citadel Advisors's AGTC Position: Q4 2022 in Review
Citadel Advisors sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 423,709 shares — an estimated $115K sold.
Citadel Advisors first reported a position in AGTC in Q1 2015 and held it in 15 quarters. The position peaked at $1.14M in Q1 2016. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.
- Citadel Advisors reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 423,709 Applied Genetic Technologies Corporation shares in Q4 2022, an estimated $115K.
- Citadel Advisors first reported a position in Applied Genetic Technologies Corporation in Q1 2015 and held it in 15 quarters.
- Citadel Advisors's Applied Genetic Technologies Corporation position peaked at $1.14M in Q1 2016.
- 0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.